PUBLISHER: The Business Research Company | PRODUCT CODE: 1414444
PUBLISHER: The Business Research Company | PRODUCT CODE: 1414444
Nephrology Drugs Global Market Report 2024
“Nephrology Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nephrology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nephrology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The nephrology drugs market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Scope
Markets Covered:
- 1) By Drugs: Antihypertensive Agents; Erythropoiesis-Stimulating Agents; Diuretics; ACE Inhibitors; Antidiabetic Agents; Other Drugs
- 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
- 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
- Companies Mentioned: AstraZeneca plc; AbbVie Inc.; Akebia Therapeutics Inc.; Amgen Inc.; F. Hoffmann-La Roche AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Executive Summary
Nephrology drugs, also known as renal drugs, are medications primarily aimed at kidney care, often targeting high blood pressure and hypertension. They're employed to improve kidney function and slow down disease progression, minimizing further harm to the body.
Key drug types in nephrology include antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and others. Antihypertensive drugs, for instance, are a diverse class used to manage high blood pressure, offering various mechanisms of action. These medications are administered through different routes such as oral, parenteral, and others, and are distributed through hospital pharmacies, online platforms, and retail pharmacies. Major users include hospitals, homecare settings, specialty clinics, and various other end-users.
The nephrology drug market research report is one of a series of new reports from The Business Research Company that provides nephrology drug market statistics, including nephrology drug industry global market size, regional shares, competitors with a nephrology drug market share, detailed nephrology drug market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drug industry. This nephrology drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nephrology drugs market size has grown strongly in recent years. It will grow from $16.18 billion in 2023 to $17.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. Historical growth can be attributed to several factors, including the increasing prevalence of chronic kidney diseases (CKD), advancements in drug development, greater awareness and improved diagnosis, government initiatives and healthcare policies supporting kidney care, and the rising incidence of diabetes, a significant contributing factor to CKD.
The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. Anticipated growth in the upcoming period is linked to emerging therapies and innovative drug developments in nephrology, the adoption of precision medicine and personalized treatment approaches, a steady increase in healthcare expenditure, the rise of telehealth and remote patient monitoring, and global health initiatives focused on kidney care.
The expanding prevalence of chronic kidney disease is anticipated to drive growth in the nephrology drugs market. Chronic kidney disease results from gradual kidney damage, leading to reduced blood filtration and potential waste buildup in the body. Nephrology drugs play a vital role in managing this condition, aiming to improve kidney function and slow disease progression. Notably, reports from the Centers for Disease Control and Prevention in July 2022 estimated over 37 million diagnosed cases of chronic kidney disease in the US, primarily affecting individuals aged 65 or older. Similarly, the Kidney Foundation of Canada reported 4 million Canadians grappling with kidney diseases, with diabetes being a prominent contributor to kidney failure, a trend expected to rise further.
The rising incidence of diabetes and hypertension is set to propel the nephrology drug market forward. Diabetes, characterized by high blood glucose levels due to insulin-related issues, and hypertension, denoting consistently high blood pressure, are increasingly prevalent conditions. Both ailments often lead to renal complications, creating a heightened demand for nephrology medications. Notably, the World Health Organization's June 2022 data registered over 2.5 million hypertension patients across 15,000 health institutions, while the Centers for Disease Control's 2022 report identified an estimated 37.3 million global cases of diabetes. Consequently, the prevalence of diabetes and hypertension drives the demand for nephrology drugs due to their association with kidney issues.
Product innovation stands as a prominent trend shaping the nephrology drug market. Key industry players are actively introducing novel drugs and solutions to maintain market relevance. For instance, in March 2022, Zydus Lifesciences Limited launched Oxemia (desidustat), an oral medication for chronic kidney disease. This innovative small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor has shown promise in Phase III trials, exhibiting positive safety profiles and beneficial effects on anemia, iron mobilization, and LDL-C reduction in CKD patients. Additionally, this innovation is positioned to alleviate the disease burden by providing cost-effective treatment and enhancing patients' quality of life.
Major companies in the nephrology drugs market prioritize obtaining approvals for innovative products, such as the US Food and Drug Administration's approval of Jardiance (empagliflozin). This medication, belonging to the SGLT-2 family for type 2 diabetes, enhances glucose excretion via the kidneys. In January 2023, Eli Lilly and Company, in collaboration with Boehringer Ingelheim, announced FDA approval of Jardiance tablets. These tablets are being investigated as a potential treatment to reduce the risk of advancing kidney disease and cardiovascular death in adults with chronic kidney disease, signifying a concerted effort among pharmaceutical giants to address evolving consumer needs through innovation and regulatory milestones.
In December 2021, CSL Behring AG, a pharmaceutical company based in Switzerland, completed the acquisition of Vifor Pharma AG for $11.7 billion. This strategic move significantly broadens CSL Behring AG's product portfolio, bringing in a comprehensive line of nephrology products that effectively tackle various conditions, including iron deficiency. Vifor Pharma AG, renowned for its global presence and focus on developing solutions for dialysis and nephrology, aligns seamlessly with CSL Behring AG's goals for expansion, diversification, and product enrichment.
Major companies operating in the nephrology drugs market report are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc
North America was the largest region in the nephrology drug market in 2023. Europe will be the second-largest growing region in the nephrology drug market in 2023. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary
2. Nephrology Drugs Market Characteristics
3. Nephrology Drugs Market Trends And Strategies
4. Nephrology Drugs Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On the Market
- 4.2. Ukraine-Russia War Impact On the Market
- 4.3. COVID-19 Impact On the Market
5. Global Nephrology Drugs Market Size and Growth
- 5.1. Global Nephrology Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Nephrology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Nephrology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Nephrology Drugs Market Segmentation
- 6.1. Global Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Antihypertensive Agents
- Erythropoiesis-Stimulating Agents
- Diuretics
- ACE Inhibitors
- Antidiabetic Agents
- Other Drugs
- 6.2. Global Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Oral
- Parenteral
- Other Route Of Administration
- 6.3. Global Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.4. Global Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
7. Nephrology Drugs Market Regional And Country Analysis
- 7.1. Global Nephrology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Nephrology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Nephrology Drugs Market
- 8.1. Asia-Pacific Nephrology Drugs Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Nephrology Drugs Market
- 9.1. China Nephrology Drugs Market Overview
- 9.2. China Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Nephrology Drugs Market
- 10.1. India Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Nephrology Drugs Market
- 11.1. Japan Nephrology Drugs Market Overview
- 11.2. Japan Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Nephrology Drugs Market
- 12.1. Australia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Nephrology Drugs Market
- 13.1. Indonesia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Nephrology Drugs Market
- 14.1. South Korea Nephrology Drugs Market Overview
- 14.2. South Korea Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Nephrology Drugs Market
- 15.1. Western Europe Nephrology Drugs Market Overview
- 15.2. Western Europe Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Nephrology Drugs Market
- 16.1. UK Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Nephrology Drugs Market
- 17.1. Germany Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Nephrology Drugs Market
- 18.1. France Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Nephrology Drugs Market
- 19.1. Italy Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Nephrology Drugs Market
- 20.1. Spain Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.3. Spain Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Nephrology Drugs Market
- 21.1. Eastern Europe Nephrology Drugs Market Overview
- 21.2. Eastern Europe Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Nephrology Drugs Market
- 22.1. Russia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Nephrology Drugs Market
- 23.1. North America Nephrology Drugs Market Overview
- 23.2. North America Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Nephrology Drugs Market
- 24.1. USA Nephrology Drugs Market Overview
- 24.2. USA Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Nephrology Drugs Market
- 25.1. Canada Nephrology Drugs Market Overview
- 25.2. Canada Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Nephrology Drugs Market
- 26.1. South America Nephrology Drugs Market Overview
- 26.2. South America Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Nephrology Drugs Market
- 27.1. Brazil Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Nephrology Drugs Market
- 28.1. Middle East Nephrology Drugs Market Overview
- 28.2. Middle East Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Nephrology Drugs Market
- 29.1. Africa Nephrology Drugs Market Overview
- 29.2. Africa Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Nephrology Drugs Market Competitive Landscape And Company Profiles
- 30.1. Nephrology Drugs Market Competitive Landscape
- 30.2. Nephrology Drugs Market Company Profiles
- 30.2.1. AstraZeneca plc
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. AbbVie Inc.
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Akebia Therapeutics Inc.
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. Amgen Inc.
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. F. Hoffmann-La Roche AG
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. AstraZeneca plc
31. Global Nephrology Drugs Market Competitive Benchmarking
32. Global Nephrology Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Nephrology Drugs Market
34. Nephrology Drugs Market Future Outlook and Potential Analysis
- 34.1 Nephrology Drugs Market In 2028 - Countries Offering Most New Opportunities
- 34.2 Nephrology Drugs Market In 2028 - Segments Offering Most New Opportunities
- 34.3 Nephrology Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies
35. Appendix
- 35.1. Abbreviations
- 35.2. Currencies
- 35.3. Historic And Forecast Inflation Rates
- 35.4. Research Inquiries
- 35.5. The Business Research Company
- 35.6. Copyright And Disclaimer
